Methods and compositions are provided for the treatment and/or diagnosis of disease caused by forms of multiple sclerosis that under-express and forms that over-express CD127. In specific examples, the methods for treating CD127-low MS comprise administering an effective amount of IL-7 or an ...
acts based on ICH rules are also in place in other parts of the world and describe the path of new medicines from discovery to routine use. This path for cellular drugs is similar to that for other drugs. It starts from preclinical assessment, which establishes the most important toxic, pha...
The aim of our study was to analyze the dropout rate in patients with relapsing-remitting multiple sclerosis (RRMS) under long-term treatment with the thre... Dieter,Linden - 《Lancet》 被引量: 38发表: 1998年 Interferon β treatment for multiple sclerosis The aim of our study was to analyz...
Treatment of multiple sclerosis 专利名称：Treatment of multiple sclerosis 发明人：ミラー， スティーブン ディー．,フレデリック，テラ ジェイ．申请号：JP2009535487 申请日：20071102 公开号：JP2010509235A 公开日：20100325 专利内容由知识产权出版社提供 摘要： The present invention relates to a ...
COMBINATION TREATMENT FOR MULTIPLE SCLEROSIS 专利名称：COMBINATION TREATMENT FOR MULTIPLE SCLEROSIS 发明人：DE LUCA, Giampiero 申请号：EP05823965.8 申请日：20051220 公开号：EP1835922A1 公开日：20070926 专利内容由知识产权出版社提供 摘要：This invention is directed towards treatments for multiple sclerosis ...
Interferon-β is a current treatment for multiple sclerosis (MS). Interferon-β is thought to exert its therapeutic effects on MS by down-modulating the immune response by multiple potential pathways. Here, we document that treatment of MS patients with interferon β-1a (Rebif) results in a si...
Multiple sclerosis commonly affects the cerebellum, the portion of the brain responsible for balance and fine motor coordination. Consequently, people with multiple sclerosis often have difficulty maintaining their balance when walking and performing delicate tasks with their hands. The unexplained dropping ...
Interferon-β treatment for multiple sclerosis Multiple sclerosis (MS) is the leading nontraumatic cause of neurologic disability in young adults. Interferon-尾, approved for use in 1993, was the first ... RA Bermel,RA Rudick - 《Neurotherapeutics》 被引量: 107发表: 2007年 Interferon β1a (Av...
Immunomodulatory Agents for the Treatment of Relapsing Multiple Sclerosis: A Systematic Review. Background: Within the past 10 years, several immunomodulatory agents (IMAs) have become available for the treatment of relapsing multiple sclerosis (MS), ... Galetta,Steven,L.,... - 《Archives of Inte...
Fingolimod (Gilenya) is the first oral immunomodulating drug approved for relapsing–remitting multiple sclerosis. Its novel mechanism of action inhibits the egress of autoreactive B and T cells from lymph nodes, thus preventing them from crossing into the CNS. Two recent large Phase III clinical ...